Restricted Stock Purchase Agreement with William J. Sasiela



 Exhibit 10.11 
 RESTRICTED STOCK PURCHASE AGREEMENT 
 THIS
RESTRICTED STOCK PURCHASE AGREEMENT (this “Agreement”) is entered into as of the 1st day of December 2005, by and between Aegerion
Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”), and William J. Sasiela (the “Equity Participant”). 
 WITNESSETH: 
 WHEREAS, the Corporation desires to issue to the Equity Participant, and the Equity
Participant desires to purchase from the Corporation, shares of the Corporation’s Common Stock, $0.001 par value per share (the “Common Stock”). 
 NOW, THEREFORE, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties do hereby agree as follows: 
 SECTION 1. Definitions. 
 As used in this Agreement, the following terms shall have the following
respective meanings: 
 “Cause” shall have the meaning set forth in the Employment Agreement. 
 “Code” shall mean the Internal Revenue Code of 1986, as amended, and the regulations promulgated thereunder. 
 “Commission” shall mean the Securities and Exchange Commission or any other Federal agency administering the Securities Act at the
applicable time. 
 “Consideration” shall have the meaning set forth in Section 2.1. 
 “Employment Agreement” shall mean the Employment Agreement proposed to be entered into by and between the Corporation and the Equity
Participant pursuant to which the Equity Participant will be employed as the full-time Senior Vice President Clinical Development and Chief Medical Officer of the Corporation. 
 “Equity Stock” shall have the meaning set forth in Rule 3a11-1 under the Securities Exchange Act of 1934, as amended, and any successor
statute and the rules and regulations thereunder, as shall be in effect from time to time. 
 “Executive Commencement Date”
shall have the meaning set forth in the Term Sheet. 







 “Fair Market Value” shall mean the fair market value, with respect to any Share, as
determined by the Board of Directors of the Corporation. 
 “Family” shall mean any spouse, lineal ancestor or descendant,
or sibling or any trust for the exclusive benefit of any of the foregoing and/or the Equity Participant. 
 “Group” shall
mean as to (a) a partnership, any or all of its general or limited partners or any “affiliate” thereof (as defined by Rule 405 promulgated under the Securities Act), (b) a trust, any of the beneficiaries, settlers or grantors now
existing or hereafter arising of, or any Person under common control with, such trust, (c) a corporation, any of its stockholders, any subsidiary of such corporation or any corporation which is under common control with such corporation, or any
directors, officers or employees of such corporation, and (d) a limited liability company, any of its members. 
 “Initial
Public Offering” shall mean the Corporation’s initial distribution of New Securities in an underwritten Public Offering to the general public pursuant to a registration statement filed with and declared effective by the Commission
pursuant to the Securities Act at a price per New Security of not less than the product of three (3) and the original purchase price per share for the Corporation’s initial round of Series A Preferred Stock (as adjusted for stock splits,
stock dividends or similar recapitalizations) and resulting in net proceeds to the Corporation of not less than $40 million. 
 “IRS” shall mean the Internal Revenue Service. 
 “New Securities” shall mean any Equity Stock,
including, but not limited to, shares of Common Stock, any security which is convertible into or exercisable or exchangeable for Common Stock, or any right, option or warrant to acquire any Common Stock. 
 “Original Cost Per Share” shall have the meaning set forth in Section 2.1. 
 “Person” shall mean and include a natural person, a corporation, a partnership, a limited liability company, a trust, an unincorporated
organization, an educational institution, a government or any department, agency or political subdivision thereof, or any other entity. 
 “Preferred Shares” shall mean, at the applicable time, all issued and outstanding shares, if any, of the Corporation’s preferred stock. 
 “Public Offering” shall mean a distribution of New Securities in a firm commitment underwritten public offering to the general public pursuant to a registration statement filed with and declared
effective by the Commission pursuant to the Securities Act. 
 “Released Shares” shall mean Shares that are not Unreleased
Shares. 
  

 2 








 “Securities Act” shall mean the Securities Act of 1933, as amended, and any successor
statute and the rules and regulations of the Commission thereunder, as shall be in effect at the applicable time. 
 “Shares” shall have the meaning set forth in Section 2.1. 
 “Term Sheet” shall mean
the term sheet, dated as of July 27, 2005, by and between the Corporation and the Equity Participant. 
 “Transfer”
shall include any direct or indirect sale, assignment, transfer, pledge (but not including a pledge in favor of the Corporation), hypothecation or other disposition of any Shares or of any legal or beneficial interest therein. 
 “Unreleased Shares” means Shares that in accordance with Section 3.1, have not been released and are subject to repurchase
by the Corporation at the Original Cost Per Share pursuant to Section 4.1. 
 SECTION 2. Issuance of Common Stock. 
 2.1 Subject to the terms and conditions contained herein, the Corporation hereby sells to the Equity Participant, and the Equity Participant hereby
purchases from the Corporation, 500,000 shares of Common Stock (the “Shares”) for a purchase price of $.001 per share (the “Original Cost Per Share”) or the aggregate purchase price of $500 (the
“Consideration”). Simultaneously with execution and delivery hereof, the Equity Participant is delivering to the Corporation a check or wire transfer of funds in the aggregate amount of the Consideration. 
 2.2 The Equity Participant, in his sole discretion, may make an effective election with the IRS under Section 83(b) of the Code and the regulations
promulgated thereunder in the form of Exhibit A attached hereto. The Equity Participant understands that under applicable law such election must be filed with the IRS no later than thirty (30) days after any acquisition of the Shares to
be effective. If the Equity Participant files an effective election, the excess of the fair value of the Shares (which the IRS may assert is different from the fair value determined by the Equity Participant) covered by such election over the amount
paid by the Equity Participant for the Shares shall be treated as ordinary income received by the Equity Participant. If the Equity Participant does not file an effective election, future appreciation on the Shares will generally be taxable as
ordinary income when the right of repurchase lapses as to such Shares pursuant to this Agreement The foregoing is merely a brief summary of complex tax regulations, and therefore, the Equity Participant is strongly advised to consult with his own
tax advisors. 
 2.3 In the event that the Equity Participant files the election referred to in Section 2.2 above, the Equity
Participant will provide the Corporation with a copy of such election as filed. 
  

 3 








 SECTION 3. Repurchase Rights related to Common Stock. 
 3.1 Except as otherwise provided in Sections 3.2 and 3.3 (a) twenty-five percent
(25%) of the Shares shall become Released Shares on the first anniversary of the Executive Commencement Date (the “First Anniversary”), and (b) after the First Anniversary, the remaining seventy-five percent (75%) of
the Shares shall become Released Shares ratably over a three (3) year period at the rate of one-twelfth (1/12) of the amount thereof at the end of each quarter anniversary of the First Anniversary, as the result of which the Shares shall
become fully (100%) Released Shares upon the fourth (4th) anniversary of the Executive Commencement; Date; provided, however, that in the event
the Equity Participant’s employment is terminated for any reason (include by the Corporation with or without Cause), the Shares which are Unreleased in the date of such termination shall remain Unreleased Shares. 
 3.2 Notwithstanding the foregoing, in the event the Equity Participant’s employment is terminated without Cause in relation to the sale or other
disposition of all or substantially all of the Corporation’s assets or a change in ownership in a single transaction or series of related transactions of fifty percent (50%) or more of the Corporation’s stock, the Shares which remain
unreleased at the time of termination, after the release of those Shares pursuant to Section 3 2 shall be released on the date of such termination and become Released Shares; provided, however that this provision shall not apply in the
event of any equity financings of the Corporation. 
 3.3 Except as provided for in Section 3.2 above, in the event the Equity
Participant’s employment is terminated without Cause, twenty-five percent (25%) of the Unreleased Shares on the date of such termination shall be released on the date of such termination and become Released Shares. 
 SECTION 4. Termination of Relationship. 
 4.1 In the
event that the Equity Participant’s employment is terminated for any reason (with or without Cause), the Corporation shall have the right to purchase from the Equity Participant, and if the Corporation exercises its option pursuant to this
Section 4, the Equity Participant shall sell to the Corporation upon the exercise of such right, (1) all of the Equity Participant’s Unreleased Shares (rounded up to the nearest whole Share) at the Original Cost Per Share, and
(2) all of the Equity Participant’s Released Shares (rounded up to the nearest whole Share) at the Fair Market value per Share; provided, however, that if the Equity Participant’s employment is terminated by the Corporation for Cause,
the purchase price for any Released Shares shall be the Original Cost Per Share. 
 4.2 The number of Shares subject to purchase pursuant to
Section 4.1 shall be adjusted to give effect to any stock dividend, or other distribution of stock made on or in respect of such Shares, or any subdivision, combination or reclassification of the outstanding capital stock of the
Corporation or received in exchange for the Shares. 
  

 4 








 4.3 In order to exercise the option to purchase the Equity Participant’s Shares under this
Section 4, the Corporation shall deliver a written notice to the Equity Participant (the “Share Repurchase Notice”), indicating its election to purchase any or all of the Shares and specifying the number of Unreleased
Shares and Released Shares, if applicable, which the Corporation elects to purchase and the purchase price therefor, within ninety (90) days after the Equity Participant’s termination. 
 4.4 The repurchase of Shares hereunder shall be made on a date within sixty (60) days of the delivery of the Share Repurchase Notice, by delivery of
payment to the Equity Participant, by check or wire transfer, against receipt of one or more certificates, properly endorsed, evidencing the Equity Participant’s Unreleased and/or Released Shares, if applicable, to be so purchased. If the
repurchase is not consummated by such date, the Corporation may deliver to the Equity Participant by check or wire transfer the applicable repurchase price for the Unreleased Shares and/or Released Shares, if applicable, to be repurchased and may
cancel the certificates evidencing such Unreleased Shares and/or Released Shares, if applicable, on the books and records of the Corporation. 
 4.5 Notwithstanding anything to the contrary contained in this Agreement, all repurchases of Shares by the Corporation shall be subject to applicable restrictions contained in federal law, the Delaware General Corporation Law and in the
Corporation’s debt and equity financing agreements. Notwithstanding anything to the contrary contained in this Agreement, if any such restrictions prohibit or otherwise delay the repurchase of any Shares thereunder which the Corporation is
otherwise entitled to make, the Corporation may make such repurchases within sixty (60) days of the date that it is permitted to do so under such restrictions. 
 4.6 In the event that any Shares are the subject of repurchase by the Corporation pursuant to this Section 4, the Equity Participant and his successors, assigns or representatives will take all steps
necessary and desirable to obtain all required third-party, governmental and regulatory consents and approvals and take all other actions necessary and desirable to facilitate consummation of such repurchase(s) in a timely manner as are requested by
the Corporation. 
 SECTION 5. Legend on Shares and Notice of Transfer. 
 5.1 Restrictive Legends. 
 (a) Each certificate evidencing Shares, and each certificate evidencing
Shares held by subsequent transferees of any such certificate, shall (unless otherwise permitted by the provisions of Section 5.2, hereof) be stamped or otherwise imprinted with a legend in substantially the following form: 

THE SECURITIES REPRESENTED BY THIS CERTIFICATE HAVE BEEN ACQUIRED FOR INVESTMENT AND HAVE NOT BEEN REGISTERED UNDER THE SECURITIES ACT OF 

  

 5 








 
1933, AS AMENDED, OR ANY STATE SECURITIES LAW. THESE SECURITIES MAY NOT BE SOLD OR TRANSFERRED IN THE ABSENCE OF SUCH REGISTRATION OR ANY EXEMPTION THEREFROM
UNDER THE SECURITIES ACT OF 1933, AS AMENDED, OR ANY APPLICABLE STATE SECURITIES LAW. 
 (b) Each certificate evidencing Shares, and each
certificate evidencing Shares held by subsequent transferees of any such certificate, shall also be stamped or otherwise imprinted with a legend in substantially the following form: 
 ADDITIONALLY, THE TRANSFER OF THESE SECURITIES IS SUBJECT TO THE TERMS AND CONDITIONS OF A RESTRICTED STOCK PURCHASE AGREEMENT EFFECTIVE AS OF OCTOBER 14,
2005, BETWEEN AEGERION PHARMACEUTICALS, INC. AND THE HOLDER OF RECORD OF THIS CERTIFICATE AND NO SALE, ASSIGNMENT, TRANSFER, PLEDGE, HYPOTHECATION OR OTHER DISPOSITION OF SUCH SECURITIES SHALL BE VALID OR EFFECTIVE EXCEPT IN ACCORDANCE WITH SUCH
AGREEMENT AND UNTIL SUCH TERMS AND CONDITIONS HAVE BEEN FULFILLED. COPIES OF SUCH AGREEMENT MAY BE OBTAINED AT NO COST BY WRITTEN REQUEST MADE BY THE HOLDER OF RECORD OF THIS CERTIFICATE TO THE SECRETARY OF AEGERION PHARMACEUTICALS, INC. 

5.2 Notice of Transfer. 
 (a) The
Equity Participant, and any other holder of any Shares by acceptance thereof, agrees that, prior to any Transfer of any Shares, such holder will give written notice to the Corporation of such holder’s intention to effect such Transfer and to
comply in all other respects with the provisions of this Section 5.2. Each such notice shall contain (i) a statement setting forth the intention of said holder’s prospective transferee with respect to its retention or
disposition of said Shares; and (ii) unless waived by the Corporation, an opinion of counsel for said holder as to the necessity or non-necessity for registration under the Securities Act and applicable state securities laws in connection with
such Transfer and stating the factual and statutory basis relied upon by counsel. The following provisions shall then apply: 
 (i) If the proposed Transfer of Shares may be effected without registration or qualification under the Securities Act and any applicable state securities laws, then the registered holder of such Shares shall be entitled to Transfer such
Shares in accordance with Section 5 hereof and the intended method of disposition specified in the statement delivered by said holder to the Corporation. 
  

 6 








 (ii) If the proposed Transfer of such Shares may not be effected without registration
under the Securities Act or registration or qualification under any applicable state securities laws, the registered holder of such Shares shall not be entitled to Transfer such Shares pursuant to Section 6 until the requisite
registration or qualification is effective. 
 (b) Notwithstanding the provisions of Section 5.2(a), in the case of a Transfer by
a holder to a member of such holder’s Family or Group, no such opinion of counsel shall be necessary; provided, that the transferee agrees in writing to be subject to Section 5 hereof to the same extent as if such transferee were
originally a signatory to this Agreement. 
 (c) Each certificate evidencing the Shares issued upon such Transfer (and each certificate
evidencing any untransferred balance of such Shares) shall bear the legend set forth in Section 5.1(a) hereof unless (i) in the opinion of counsel (acceptable to the Corporation) addressed to the Corporation the registration of
future Transfers is not required by the applicable provisions of the Securities Act or applicable state securities laws; (ii) the Corporation shall have waived the requirement of such legend; or (iii) in the reasonable opinion of counsel
to the Corporation, such Transfer shall have been made in connection with an effective registration statement filed pursuant to the Securities Act or in compliance with the requirements of Rule 144 or Rule 144A (or any similar or successor rule)
promulgated under the Securities Act, and in compliance with applicable state securities laws. 
 (d) Each certificate evidencing the Shares
issued upon such Transfer (and each certificate evidencing any untransferred balance of such Shares) shall bear the legend set forth in Section 5.1(b) hereof for so long as this Agreement remains in effect. In the event of the
termination of this Agreement, the holder of Shares may request that the Corporation issue a new certificate not bearing the legend set forth in Section 5.1(b) hereof. 
 SECTION 6. Covenants of the Equity Participant and the Corporation. 
 6.1 Permitted Transfers.

 (a) Neither the Equity Participant nor any permitted transferee of the Equity Participant shall Transfer all or any of the Shares to
any Person except in accordance with Sections 3 and 4 hereof. Notwithstanding anything to the contrary contained herein (other than Section 3 hereof), the Equity Participant (and any permitted transferee of the Equity
Participant) may Transfer all or any portion of his Shares: (i) if the stockholder is a limited partnership or a trust, to any member of the Group of which the Equity Participant (or such permitted transferee) is a member, provided, that such
transferee shall agree in writing with the Corporation, prior to and as a condition precedent to such Transfer, to be bound by all of the provisions of this Agreement; (ii) if the stockholder is a corporation or a limited liability company, to
any member of its Group; provided, that such transferee shall agree in writing with the Corporation, prior to and as a condition precedent to such Transfer, to be bound by all of the provisions of this 

  

 7 








 
Agreement; (iii) if the stockholder is an individual, to any member of the Family of such stockholder, provided, that such new transferee shall agree in
writing with the Corporation, prior to and as a condition precedent to such Transfer, to be bound by all of the provisions of this Agreement and, provided, further, that the interests in any Family trusts shall be nontransferable; and (iv) if
the transferor is a permitted transferee of the Equity Participant by will or the laws of descent and distribution, provided that each such new transferee shall be bound by all of the provisions of this Agreement to the same extent as if such
transferee was a party hereto. 
 (b) If requested in writing by the managing underwriters, if any, of any Initial Public Offering, the
Equity Participant agrees not to offer, sell, contract to sell or otherwise dispose of any Shares except as part of such Initial Public Offering within thirty (30) days before or one hundred and eighty (180) days after the effective date
of the registration statement filed with respect to said offering; provided, however, that this restriction will not apply to transfers permitted under Section 6.1 (a) provided such transferee agrees to be bound by the restriction
contained in this Section 6.1(b). 
 6.2 Right of First Offer on Dispositions. 
 (a) If Equity Participant desires to Transfer all or any part of his Shares pursuant to this Section 6.2 at any time prior to completion of
the Corporation’s Initial Public Offering (other than pursuant to Section 6.1(a) or 6 3 hereof), Equity Participant shall submit a written offer (the “Offer”) to sell such Shares (the “Offered
Shares”) to the Corporation, which Offer shall specify the number of Offered Shares proposed to be sold, the total number of Shares owned by Equity Participant, and the terms and conditions, including price, at which the Shares are being
offered. 
 (b) The Corporation shall have the right to purchase any or all of the Offered Shares on the same terms and conditions specified
in the Offer. 
 (c) If the Corporation desires to purchase any or all of the Offered Shares on the same terms and conditions specified in
the Offer, the Corporation shall deliver its acceptance (an “Acceptance”) to Equity Participant, which Acceptance shall confirm that the Corporation desires to purchase any or all of the Offered Shares and the number of Shares the
Corporation desires to purchase and shall be delivered in person or mailed to Equity Participant at the address set forth in the Offer within twenty (20) days of the date the Offer was made by Equity Participant pursuant to
Section 6.2(a). 
 (d) If the Corporation elects to purchase any or all of the Offered Shares, sale of the Offered Shares
pursuant to this Section 6.2, shall be made at the offices of the Corporation on the 30th day following the expiration of the 20-day period described above (or if such 30th 

  

 8 








 
day is not a business day, then on the next succeeding business day). Such sale shall be effected by Equity Participant’s delivery to the Corporation of
a certificate or certificates evidencing the Offered Shares to be purchased by it, duly endorsed for transfer to the Corporation, which Offered Shares shall be delivered free and clear of all liens, charges, claims and encumbrances of any nature
whatsoever, against payment to Equity Participant of the purchase price therefor by the Corporation. Payment for the Offered Shares shall be made as provided in the Offer or by wire transfer or certified check. 
 (e) If the Corporation does not elect to purchase all of the Offered Shares, then the Offered Shares (less the amount to be purchased by the Corporation)
may be sold by Equity Participant at any time within one hundred twenty (120) days after the date the Corporation responded to the Offer was made by Equity Participant pursuant to Section 6.2(a). Any such sale shall be upon terms
and conditions, including price, no more favorable to the proposed transferee than those specified in the Offer. Any Offered Shares not sold within such 120-day period shall continue to be subject to the requirements of a prior offer pursuant to
this Section 6.2. 
 6.3 Drag Along. Subject to Section 6.2, above, anything in this Agreement to the contrary
notwithstanding, in the event that (i) the Board of Directors of the Corporation by unanimous vote or unanimous written consent and/or the holders of more than fifty percent (50%) of the then outstanding Common Stock by vote or written
consent approves a transaction pursuant to which any Person or Persons not affiliated with any of the holders of any Common Stock will acquire fifty percent (50%) or more of the Common Stock of the Corporation (by stock purchase, merger or
otherwise) or all or substantially all of the assets of the Corporation, upon the written request of the holders of more than fifty percent (50/100) of the Common Stock, the Equity Participant agrees to offer to sell all of his Shares, and to
sell all of his Shares (or, if such proposed transaction involves the sale of less than one hundred percent (100%) of the outstanding Common Stock, a proportionate amount of his Shares), to such Person or Persons or to vote all of his Shares in
favor of the sale of assets, as the case may be, in either case upon the terms and conditions of the transaction approved by the Board of Directors of the Corporation and/or the holders of more than fifty percent (50%) of the Common Stock;
provided, however, that the Equity Participant’s obligation to sell his Shares pursuant to this Section 6.3, shall only apply if all of the Shares are to be sold on the same terms and conditions as the shares of such other Person or
Persons. For purposes of this Section 6.3. each Preferred Share shall be deemed to be the number of shares of Common Stock into which such Preferred Share is then convertible. 
 6.4 “Piggyback” Registrations. 
 (a) If the Corporation at any time proposes to register any of its securities under the Securities Act on Form S-l, S-2 or S-3 or on any other form upon which the Common Stock may be registered for sale to the general public, other than on
Form S-4 or S-8 or other similar registration statement not generally used by an issuer in connection with raising capital, 

  

 9 








 
whether for its own account or for the account of others, the Corporation will at each such time promptly give written notice to the Equity Participant of
such proposal, which shall set forth information, to the extent then known, as to offering price or range, the number of shares to be offered, the proposed manner of distribution and the proposed managing underwriter(s) of the offering. Upon the
written request of the Equity Participant given within twenty (20) days after the Corporation has given such notice and subject to any rights of the holders of Preferred Shares of the Corporation, the Corporation will cause the Shares which the
Corporation has been requested to register by the Equity Participant to be registered under the Securities Act (and any related qualification under blue sky laws or other compliance), all to the extent required to permit the sale or other
disposition by the Equity Participant of the Shares so registered. 
 (b) If securities are to be registered for sale under a registration
and are to be distributed for the account of the Corporation by or through a firm of underwriter(s), then, subject to the rights of the holders of Preferred Shares of the Corporation, any Shares which the Corporation has been requested to register
pursuant to clause (a) of this Section 6.4 shall also be included in such underwriting on the same terms as other securities of the same class as the Shares included in such underwriting; provided, that if, in the written opinion of
the managing underwriter(s), the total amount of such securities to be so registered, when added to the Shares, will exceed the maximum amount of the Corporation’s securities which can be marketed (1) at a price reasonably related to their
then current market value, or (ii) without otherwise materially and adversely affecting the entire offering, then (subject to clause (d) of this Section 6.4) the Corporation shall exclude from such underwriting, first, the
number of Shares being sold for the account of the Equity Participant as is necessary, in the opinion of the managing underwriter(s), to reduce the size of the offering provided , however, that the number of securities to be requested
to be sold in the offering by officers, directors and other founding stockholders are likewise reduced pro rata based upon the number of securities requested to be registered. 
 (c) If securities are to be registered for sale under a registration and are to be distributed for the account of holders of Common Stock held by third
parties or holders (other than the Corporation) of other securities of the Corporation other than Common Stock by or through a firm of underwriters) of recognized standing under underwriting terms appropriate for such transaction, then any Shares
which the Corporation has been requested to register pursuant to clause (a) of this Section 6.4 shall also be included in such underwriting on the same terms as other securities included in such underwriting, provided, that it in
the written opinion of the managing underwriter(s), the total amount of such securities to be so registered, when added to such Shares, will exceed the maximum amount of the Corporation’s securities which can be marketed (i) at a price
reasonably related to their then current market value, or (ii) without otherwise materially and adversely affecting the entire offering, then the Corporation shall exclude from such underwriting the number of Shares and other securities, pro
rata to the extent practicable, on the basis of the number of securities requested to be registered, as is necessary in e opinion of the managing underwriter(s) to reduce the size of the offering; provided, however, that the number of
securities to be requested to be sold in the offering by officers, directors and other founding stockholders are likewise reduced pro rata based upon the number of securities requested to be registered. 
  

 10 








 (d) Notwithstanding Sections 6.4(a), (b) and (c) the Corporation may
exclude all Shares from registration in connection with the Corporation’s Initial Public Offering if the inclusion of such Shares would, in the written opinion of the managing underwriter(s) adversely affect the marketing of the New Securities
to be sold by the Corporation therein; provided that such exclusion of Shares shall be made pro rata with all other shares of Common Stock held by third parties issued prior to the issuance and sale of the Preferred Shares; provided, further, that
such shares of Common Stock shall not include shares of Common Stock received by third parties pursuant to conversion of Preferred Shares. 
 SECTION 7.
Representations. 
 7.1 Representations of the Equity Participant. In connection with the Equity Participant’s purchase of
any Shares on the date hereof, the Equity Participant hereby represents and warrants to the Corporation as follows: 
 (a) Investment
Intent; Capacity to Protect Interests. The Equity Participant is acquiring the Shares solely for his own account for investment and not with a view to or for sale in connection with any distribution of the Shares or any portion thereof and not
with any present intention of selling, offering to sell or otherwise disposing of or distributing the Shares or any portion thereof in any transaction other than a transaction exempt from registration under the Securities Act. 
 (b) Restricted Securities. The Equity Participant understands and acknowledges that the sale of the Shares has not been registered under the
Securities Act; that the Shares must be held indefinitely unless subsequently registered under the Securities Act or an exemption from such registration is available; and that, except as provided in Section 6.3, the Corporation is under
no obligation to register the Shares. The Equity Participant has no need for liquidity relating to his investment in the Shares and is able to bear the economic risk of his investment in the Shares for an indefinite period of time. 
 (c) Disposition under Rule 144. The Equity Participant understands that the Shares are restricted securities within the meaning of Rule 144
promulgated under the Securities Act; that the exemption from registration under Rule 144 will not be available in any event for at least one (1) year from the date of purchase of any payment for the Shares, and even then will not be available
unless (i) a public trading market then exists for the Shares, (ii) adequate information concerning the Corporation is then available to the public, and (iii) other terms and conditions of Rule 144 are complied with; and that any sale
of the Shares may be made only in limited amounts in accordance with such terms and conditions. 
  

 11 








 (d) The Equity Participant has generally such knowledge and experience in business and financial matters
and with respect to investments in securities of privately held companies so as to enable him to understand and evaluate the risks and benefits of his investment in the Shares. The Equity Participant has had an opportunity to ask questions and
receive answers concerning the terms and conditions of the offering of the Shares and has had full access to or been provided with such other information concerning the Corporation as he has requested. 
 7.2 Representations of the Corporation. The Corporation represents to the Equity Participant that: 
 (a) The execution, delivery and performance by the Corporation of this Agreement and all transactions contemplated by this Agreement have been duly
authorized by all action required by law, its Certificate of Incorporation, its Bylaws or otherwise. 
 (b) This Agreement has been duly
executed and delivered by the Corporation and constitutes the legal, valid and binding obligation of the Corporation enforceable against it in accordance with its terms. 
 SECTION 8. Withholding. 
 Upon the request of the Corporation, the Equity Participant shall promptly
pay to the Corporation, or make arrangements satisfactory to the Corporation regarding payment of, any Federal, state or local taxes of any kind required by law to be withheld with respect to the Shares (or any distributions of other securities or
property (including cash) thereon or issued in replacement thereof). 
 SECTION 9. Remedies. 
 In case any one or more of the covenants and/or agreements set forth in this Agreement shall have been breached by any party hereto, the party entitled to
the benefit of such covenants or agreements may proceed to protect and enforce its rights either by suit in equity and/or by action at law, including, but not limited to, (a) an action for damages as a result of any such breach, (b) an
action for specific performance of any such covenant or agreement contained in this Agreement, and/or (c) a temporary or permanent injunction, in any case without showing any actual damage. The rights, power and remedies of the parties under
this Agreement are cumulative and not exclusive of any other agreement or law. No single or partial assertion or exercise of any right, power or remedy of a party hereunder shall preclude any other or further assertion or exercise thereof. Any
purported Transfer in violation of the provisions of this Agreement shall be null and void ab initio. 
 SECTION 10. Successors and Assigns.

 Except as otherwise expressly provided herein, this Agreement shall bind and inure to the benefit of the Corporation, the Equity
Participant, the respective successors or heirs, distributees 

  

 12 








 
and personal representatives and permitted assigns of the Corporation and the Equity Participant, and each other person who shall properly become a
registered holder of any Shares that have not theretofore been sold to the public pursuant to a registration statement under the Securities Act or Rule 144 or Rule 144A (or any similar or successor rule). 
 SECTION 11. Entire Agreement. 
 This Agreement,
together with the Employment Agreement and the Confidentiality and Assignment Agreement executed by the parties, contain the entire agreement among the parties with respect to the subject matter hereof and supersede other prior and contemporaneous
arrangements or understandings with respect thereto. 
 SECTION 12. Notices. 
 All notices, consents and other communications under this Agreement shall be in writing and shall be deemed to have bean duly given (a) when
delivered by hand, (b) one (1) business day after the business day of transmission, if sent by telex or telecopier (with receipt confirmed), provided that a copy is mailed by registered mail, return receipt requested, or (c) one
(1) business day after the business day of deposit with the carrier, if sent by Express Mail, Federal Express or other nationally-recognized express delivery service (receipt requested), in each case to the appropriate addresses, telex numbers
and telecopier numbers set forth below (or to such other addresses or telecopy numbers as a party may designate as to itself or herself by notice to the other party): 
  

			
	(a)	  	If to the Equity Participant:
		
		  	William J. Sasiela
		  	c/o Aegerion Pharmaceuticals, Inc.
		  	250 West Main Street
		  	Branford, Connecticut 06405
		
	(b)	  	If to the Corporation:
		
		  	Aegerion Pharmaceuticals, Inc.
		  	c/o Scheer & Company, Inc.
		  	250 West Main Street
		  	Branford, Connecticut 06405
		  	Telecopier: (203) 481-4164
		  	Attention: David I. Scheer, President
		
		  	with a copy to:
		
		  	Sills Cummis Epstein & Gross P.C.
		  	One Riverfront Plaza
		  	Newark, New Jersey 07102
		  	Telecopier No.: (973) 643-6500
		  	Attention: Ira A. Rosenberg, Esq.

  

 13 








 SECTION 13. Changes. 
 The terms and provisions of this Agreement may not be modified or amended, or any of the provisions hereof waived, temporarily or permanently, without the prior written consent of each of the parties hereto.

 SECTION 14. Counterparts. 
 This
Agreement may be executed in any number of counterparts, and each such counterpart shall be deemed to be an original instrument, but all such counterparts together shall constitute but one agreement and that execution may be delivered by facsimile.

 SECTION 15. Headings. 
 The benefits of
the various sections of this Agreement have been inserted for convenience of reference only and shall not be deemed to be part of this Agreement. 
 SECTION
16. Nouns and Pronouns. 
 Whenever the context may require, any pronouns used herein shall include the corresponding masculine,
feminine or neuter forms, and the singular form of names and pronouns shall include the plural and vice-versa. 
 SECTION 17. Severability.

 Any provision of this Agreement that is prohibited or unenforceable in any jurisdiction shall, as to such jurisdiction, be ineffective to
the extent of such prohibition or unenforceability. Such prohibition or unenforceability in any one jurisdiction shall not invalidate or render unenforceable such provision in any other jurisdiction. 
 SECTION 18. Governing Law; Jurisdiction. 
 This
Agreement and (unless otherwise provided) all amendments hereof and waivers and consents hereunder shall be governed by the internal law of the State of Delaware, without regard to the conflicts of law principles thereof. Each party hereby submits
itself or himself, for the sole purpose of this Agreement and any controversy arising hereunder, to the exclusive jurisdiction as follows: (i) prior to the date upon with the Corporation opens a corporate headquarters, in the state and Federal
courts located in the State of Connecticut, and (ii) after the date upon with the Corporation opens a corporate headquarters, in the state and Federal courts located in the jurisdiction where such corporate headquarters are found, and each
party waives any objection (on the grounds of lack of jurisdiction, forum non conveniens or otherwise) to the exercise of 

  

 14 








 
such jurisdiction over it or him by any such court in the appropriate jurisdiction. Each party hereby agrees that service of process may be served on it or
him by certified mail, return receipt requested, or overnight courier, sent to the address of such entity or such entity’s attorneys listed in Section 12 above (or such other address as any such party notifies the other thereof by
written notice). 
 IN WITNESS WHEREOF, the parties hereto have executed this Restricted Stock Purchase Agreement as of the date and year
first written above. 
  

			
	AEGERION PHARMACEUTICALS, INC.
		
	By:	 	 /s/ Gerald Wisler

	Name:	 	Gerald Wisler
	Title:	 	President and Chief Executive Officer
	
	 /s/ William J. Sasiela

	William J. Sasiela


  

 15 








 Exhibit A 
 Form of 83(b) Election 
 ELECTION PURSUANT TO SECTION 83(b) OF THE 
 INTERNAL REVENUE CODE 
 The undersigned hereby
makes the election authorized by Section 83(b) of the Internal Revenue Code of 1986, as amended (the “Code”) and the regulations thereunder, with respect to shares of Common Stock of Aegerion Pharmaceuticals, Inc.
(the “Company”) described below acquired by the undersigned on the date shown below. To the extent permitted, this election shall also serve as an election under analogous state law. As required by the Treasury Regulations
under Section 83(b), the undersigned supplies herewith the following information: 
 1. The undersigned’s name and address are: 
 Name: 
 Address: 
 2. The undersigned has taxpayer identification number             ; 
 3. The property with respect to which this protective election is made consists of              shares
of Common Stock of the Company. 
 4. The date on which the above-described property was transferred to the undersigned was
            . 
 5. As of the date of transfer, the property was subject to the following
substantial risk of forfeiture: 
 (a) All of the shares are subject to time vesting based on a continued business
relationship with the Company. 
 (b) All of the shares which have not been “released” are subject to repurchase by
the Company in the event the undersigned’s business relationship with the Company ceases for any reason. The purchase price for each share of Common Stock which has not yet been “released” and is subject to repurchase will be the
undersigned’s original cost per share. 
 (c) All of the shares which have been “released” are subject to
repurchase by the Company in the event the undersigned’s business relationship with the Company is terminated for Cause. The purchase price for each share of Common Stock which has been “released” and is subject to repurchase will be
the undersigned’s original cost per share. 
  

 16 








 (d) All of the shares which have been “released” are subject to repurchase by
the Company in the event the undersigned’s business relationship with the Company ceases for any reason other than Cause. The purchase price for each share of Common Stock which has been “released” and is subject to repurchase will be
the fair market value of such share. 
 6. The fair market value of the property at the time of transfer (determined without regard to any restrictions other
than restrictions which by their terms will never lapse) was $             per share. 
 7. The amount paid for the property by the undersigned was $0.001 per share (“Original Cost Per Share”). 
 A copy
of this election has been furnished to the Company, and a copy of this election will be attached to the undersigned’s federal income tax return for the year to which this election relates. 
  

			
	  

	 Name:
	 	
		
	 Date:
	 	  


  

 17 








 Amendment No. 1 to Restricted Stock Purchase Agreement 
 This Amendment No. 1 to Restricted Stock Purchase Agreement (the “Amendment”) is made as of this 13 day of June 2007, by and
between Aegerion Pharmaceuticals, Inc., a Delaware corporation (the “Corporation”) and William J. Sasiela (the “Equity Participant”), parties to that certain Restricted Stock Purchase Agreement dated as of
December 1, 2005 (the “Agreement”). Capitalized terms used herein, unless otherwise defined herein, shall have the meanings ascribed to them in the Agreement. 
 WHEREAS, the Corporation and the Equity Participant desire to amend the Agreement; and 
 WHEREAS, pursuant to Section 13 of the Agreement, a waiver, amendment or modification to the terms and provisions of the Agreement may not be
effected without the prior written consent of the Corporation and the Equity Participant. 
 NOW, THEREFORE in consideration of the
foregoing and intending to be legally bound, the Company and the Equity Participant agree as follows. 
 1. The definition of “Initial Public
Offering” contained in Section 1 of the Agreement is amended and restated in its entirety to read as follows: 
 “Initial
Public Offering” shall mean the Corporation’s initial distribution of New Securities in a firm commitment underwritten public offering to the general public pursuant to a registration statement filed with and declared effective by the
Commission pursuant to the Securities Act. 
  

	2.	Section 6.3 of the Agreement shall terminate upon an Initial Public Offering. 

 3. This Amendment shall be deemed to be a contract made under, and shall be construed in accordance with, the laws of the State of Delaware, without giving effect to conflict of interest laws principles thereof.

 4. This Amendment may be executed in multiple counterparts, each of which shall be deemed an original, but all of which together shall constitute one and
the same instrument. 
 5. Except to the extent amended hereby, the terms and provisions of the Agreement shall remain in full force and effect. 

[SIGNATURE PAGE FOLLOWS] 
  







 IN WITNESS WHEREOF, the parties hereto have executed this Amendment No. 1 to Restricted Stock
Purchase Agreement as of the date and year first written above. 
 AEGERION PHARMACEUTICALS, INC. 
 By /s/ Gerald Wisler 
 Name: Gerald Wisler 
 Title: President and Chief Executive Officer 
 /s/ William J. Sasiela 
 William J. Sasiela